12.26.18

Kala Pharmaceuticals Announces NDA for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by FDA

Source: Kala Pharmaceuticals

Kala Pharmaceuticals announced that the new drug application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a 2-week course of therapy, has been accepted for review by the FDA. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of August 15, 2019. If approved, KPI-121 0.25% is expected to be the first product indicated for the temporary relief of the signs and symptoms of dry eye disease, which would include treatment of dry eye flares.

“All currently marketed FDA-approved pharmaceutical treatments for dry eye disease are chronic therapies and are typically used in patients with chronic or persistent dry eye symptoms,” Edward Holland, MD, Director of Cornea Services, Cincinnati Eye Institute and Professor of Clinical Ophthalmology, University of Cincinnati, said in a company news release. “The vast majority of patients experience episodic dry eye flares that are characterized by acute exacerbations of signs and/or symptoms. An FDA-approved, safe and effective short-term treatment for dry eye disease, including dry eye flares, will represent an important new treatment option for patients and prescribers.”

KPI-121 0.25% utilizes Kala’s proprietary AMPPLIFY Drug Delivery Technology to enhance penetration into target tissues of the eye. In preclinical studies, the AMPPLIFY technology increased delivery of loteprednol etabonate (LE) into ocular tissues more than three-fold compared to current LE products by facilitating penetration through the tear film mucins. The AMPPLIFY technology also underpins Inveltys (loteprednol etabonate ophthalmic suspension) 1%, the first twice-a-day corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery, which was approved by the FDA in August 2018.

The NDA submission for KPI-121 0.25% was supported by data from one phase 2 and two phase 3 efficacy and safety trials, STRIDE 1 and STRIDE 2 (STRIDE – Short Term Relief In Dry Eye), studying over 2,000 patients with dry eye disease. Based upon the FDA’s recommendation, Kala also initiated an additional phase 3 clinical trial, STRIDE 3, in July 2018, evaluating KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The company expects to report topline results for STRIDE 3 in the fourth quarter of 2019.

Related Content